Commentary on the WHO classification of tumors of lymphoid tissues (2008): “Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma

Journal of Hematopathology - Tập 2 Số 2 - Trang 89-95 - 2009
Robert P. Hasserjian1,2, German Ott3, Kojo S.J. Elenitoba-Johnson4, Olga Balague-Ponz5, Daphne de Jong5, Laurence de Leval6
1Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
2Pathology, Warren 2, Massachusetts General Hospital, Boston, USA
3Department of Pathology, Robert-Bosch-Krankenhaus and Institute of Clinical Pharmacology, Stuttgart, Germany
4Department of Pathology, University of Michigan, Ann Arbor, USA
5Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
6Department of Pathology, C.H.U Sart Tilman, University of Liège, Liège, Belgium

Tóm tắt

Từ khóa


Tài liệu tham khảo

Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008). WHO Classification of tumors of Hematopoietic and Lymphoid Tissues. IARC, Lyon

Hummel M, Bentink S, Berger H et al (2006) A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 354(23):2419–2430

Dogan A, Bagdi E, Munson P, Isaacson P (2000) CD10 and bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24:846–852

Boerma EG SR, Kluin PM, Baudis M (2009) Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge Leukemia 23(2):225-234

Dave SS, Fu K, Wright GW et al (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354(23):2431–2442

Leucci E, Cocco M, Onnis A et al (2008) MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 216(4):440–450

Haralambieva E, Boerma EJ, van Imhoff GW et al (2005) Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 29(8):1086–1094

Leoncini L, Delsol G, Gascoyne RD et al (2005) Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. Histopathology 46(3):241–255

Thangavelu M, Olopade O, Beckman E et al (1990) Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer 2(2):147–158

Nakamura F, Tatsumi E, Tani K et al (1996) Coexpression of cell-surface immunoglobulin (sIg), terminal deoxynucleotidyl transferase (TdT) and recombination activating gene 1 (RAG-1): two cases and derived cell lines. Leukemia 10(7):1159–1163

van Imhoff GW, Boerma EJ, van der Holt B et al (2006) Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24(25):4135–4142

Cigudosa JC, Parsa NZ, Louie DC et al (1999) Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer 25(2):123–133

Mead GM, Barrans SL, Qian W et al (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112(6):2248–2260

Kanungo A, Medeiros LJ, Abruzzo LV, Lin P (2006) Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19(1):25–33

Hasserjian RP SR, Turbiner J, Wang S, Pinkus GD, Harris NL, Iafrate AJ (2008) BCL2, BCL6, and MYC rearrangements in follicular lymohoma: comparison of FISH and immunohistochemical results on a tissue microarray and correlation with patient outcome. Mod Pathol 21(Suppl 1):256A

Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R (2001) Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98(10):3082–3086

Macpherson N, Lesack D, Klasa R et al (1999) Small noncleaved, non-Burkitt’s (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 17(5):1558–1567

Kolman OK, Snuderl M, Ferry JA, Hochberg EP, Chen YB, Hasserjian RP, Rahemtullah A (2008) Clinicopathologic features of B-cell lymphomas with concurrent BCL-2 and c-MYC gene rearrangements. Mod Pathol 21(Suppl 1):260A

McClure RF, Remstein ED, Macon WR et al (2005) Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 29(12):1652–1660

Jacobson J, Aisenberg A, Lamarre L et al (1988) Mediastinal large cell lymphoma: an uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 62:1893–1898

Addis BJ, Isaacson PG (1986) Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology 10(4):379–390

Cazals-Hatem D, Lepage E, Brice P et al (1996) Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d’Etude des Lymphomes de l’Adulte") study. Am J Surg Pathol 20(7):877–888

Lamarre L, Jacobson JO, Aisenberg AC, Harris NL (1989) Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol 13(9):730–739

Pileri SA, Gaidano G, Zinzani PL et al (2003) Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 162(1):243–253

de Leval L, Ferry JA, Falini B, Shipp M, Harris NL (2001) Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol 25(10):1277–1282

Copie-Bergman C, Plonquet A, Alonso MA et al (2002) MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 15(11):1172–1180

Copie-Bergman C, Boulland ML, Dehoulle C et al (2003) Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 101(7):2756–2761

Calaminici M, Piper K, Lee AM, Norton AJ (2004) CD23 expression in mediastinal large B-cell lymphomas. Histopathology 45(6):619–624

Savage KJ, Monti S, Kutok JL, et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin’s lymphoma. Blood 102(12):3871-3879

Rodig SJ, Savage KJ, LaCasce AS et al (2007) Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 31(1):106–112

Rosenwald A, Wright G, Leroy K et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198(6):851–862

Rudiger T, Jaffe ES, Delsol G et al (1998) Workshop report on Hodgkin’s disease and related diseases (‘grey zone’ lymphoma). Ann Oncol 9(Suppl 5):S31–38

Calvo KR, Traverse-Glehen A, Pittaluga S, Jaffe ES (2004) Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol 11(5):227–238

Garcia JF, Mollejo M, Fraga M et al (2005) Large B-cell lymphoma with Hodgkin’s features. Histopathology 47(1):101–110

Traverse-Glehen A, Pittaluga S, Gaulard P et al (2005) Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29(11):1411–1421

Joos S, Otano-Joos MI, Ziegler S et al (1996) Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87(4):1571–1578

Joos S, Granzow M, Holtgreve-Grez H et al (2003) Hodgkin’s lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 103(4):489–495

Wessendorf S, Barth TF, Viardot A et al (2007) Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 21(12):2463–2469

Feuerhake F, Kutok JL, Monti S et al (2005) NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106(4):1392–1399

Guiter C, Dusanter-Fourt I, Copie-Bergman C et al (2004) Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 104(2):543–549

Melzner I, Bucur AJ, Bruderlein S et al (2005) Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105(6):2535–2542

Weniger MA, Melzner I, Menz CK et al (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25(18):2679–2684

Renne C, Willenbrock K, Martin-Subero JI et al (2007) High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21(4):780–787